DuPont de Nemours (DD) has been tied tightly to a number of investor positions, endorsements, and price target adjustments, while forging collaborative partnerships and presenting strong market performance. DD has established a substantive collaboration with
Epicore, aiming to improve worker safety solutions. DD has consequently been endorsed by
UBS with a buy rating and a new price target of $85 from the banking group. Equities performed strongly, surpassing Q1 earnings and revenue estimates. A series of investment firms including Tidal Investments, Vident Advisory, Delta Investment, and Woodline Partners have increased their stakes in the company.
Royal Bank of Canada significantly purchased 92,225 shares. Additionally, DD's partnership with Epicore extends their role into the field of smart wearable technology. The company received positive remarks from
Jim Cramer, even in the face of slight financial turbulence tied to an investigation by the Portnoy Law Firm. Moreover, DD has unveiled innovative chromatography technology that aims to accelerate the drug development process. Lastly, DD is anticipating strong earnings from their next quarterly earnings report.
Dupont De Nemours DD News Analytics from Sun, 08 Dec 2024 08:00:00 GMT to Sat, 24 May 2025 12:38:33 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -2
